A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis
Public ClinicalTrials.gov record NCT00267969. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Randomized, Double-blind, Placebo Controlled Trial Evaluating the Efficacy and Safety of Ustekinumab (CNTO 1275) in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis
Study identification
- NCT ID
- NCT00267969
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Centocor Research & Development, Inc.
- Industry
- Enrollment
- 766 participants
Conditions and interventions
Conditions
Interventions
- ustekinumab Drug
- placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2005
- Primary completion
- Jun 30, 2006
- Completion
- Apr 30, 2011
- Last update posted
- Jun 16, 2013
2005 – 2011
United States locations
- U.S. sites
- 28
- U.S. states
- 23
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Phoenix | Arizona | — | — |
| Not listed | Los Angeles | California | — | — |
| Not listed | Redwood City | California | — | — |
| Not listed | Santa Monica | California | — | — |
| Not listed | Denver | Colorado | — | — |
| Not listed | Wilmington | Delaware | — | — |
| Not listed | Ocala | Florida | — | — |
| Not listed | Alpharetta | Georgia | — | — |
| Not listed | Marietta | Georgia | — | — |
| Not listed | Newnan | Georgia | — | — |
| Not listed | Honolulu | Hawaii | — | — |
| Not listed | Boise | Idaho | — | — |
| Not listed | Normal | Illinois | — | — |
| Not listed | Indianapolis | Indiana | — | — |
| Not listed | Lake Charles | Louisiana | — | — |
| Not listed | Worcester | Massachusetts | — | — |
| Not listed | Fridley | Minnesota | — | — |
| Not listed | St Louis | Missouri | — | — |
| Not listed | Omaha | Nebraska | — | — |
| Not listed | East Windsor | New Jersey | — | — |
| Not listed | Albuquerque | New Mexico | — | — |
| Not listed | New York | New York | — | — |
| Not listed | Lake Oswego | Oregon | — | — |
| Not listed | Portland | Oregon | — | — |
| Not listed | Goodlettsville | Tennessee | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | Seattle | Washington | — | — |
| Not listed | Milwaukee | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00267969, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 16, 2013 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00267969 live on ClinicalTrials.gov.